1
/
of
9
Centellian24
Centellian 24 Madeca Prime Facial Toning Device - 3-in-1 Microcurrent + Hyaluronic Tox Boosting Ampoule (1.01fl oz) - Deep Moisturization & Hydration with Hyaluronic Acid, Premium Korean Skin Care
Centellian 24 Madeca Prime Facial Toning Device - 3-in-1 Microcurrent + Hyaluronic Tox Boosting Ampoule (1.01fl oz) - Deep Moisturization & Hydration with Hyaluronic Acid, Premium Korean Skin Care
Regular price
$436.52 USD
Regular price
Sale price
$436.52 USD
Unit price
/
per
Shipping calculated at checkout.
Couldn't load pickup availability
About This
- CENTELLIAN 24 MADECA PRIME FACIAL TONING DEVICE - Achieve 'glass skin' with this advanced microcurrent beauty device. Madeca Prime enhances skin radiance, improves elasticity, and boosts the absorption of your skincare products, making your complexion 1.7 times more luminous and increasing absorption by 3.3 times compared to manual application.
- TRIANGULAR HEAD FOR PRECISE APPLICATION - The unique triangular head design allows for precise application, targeting all facial contours effectively, ensuring every part of your face receives optimal care.
- HYALURONIC TOX BOOSTING AMPOULE (30 ml/1.01 fl oz) contains 250,000 ppm of HYA10 Complex made from 10 types of hyaluronic acid for deep moisturization of the skin.
- HYALURONIC ACID COMPLEX - Each bottle of Hyaluronic Tox Boosting Ampoule is specially formulated with HYA10 Complex, containing 10 different types of hyaluronic acid including Dongkook Pharmaceutical’s exclusive hyaluronic acid components to deeply moisturize dry skin for up to 120 hours.
- CENTELLIAN 24 - As a flagship derma-cosmetic brand of Dongkook Pharmaceutical, Centellian 24 seamlessly integrates over five decades of pioneering expertise in centella asiatica. Harnessing the power of this botanical marvel, Centellian 24 products are meticulously crafted to rejuvenate and nourish your skin, ensuring round-the-clock protection and vitality.
Overview
- Brand : CENTELLIAN 24
- Skin Type : All, Dry
- Style : Madeca Prime Facial Toning Device
Share








